BUDGET IMPACT OF ALBUMIN-BOUND PACLITAXEL + GEMCITABINE IN THE TREATMENT OF METASTATIC PANCREATIC CANCER
Author(s)
Binder G1, Whiting S1, Milentijevic D2, Penenberg D3, Wei X3, Kayitalire L1, Renschler MF1
1Celgene Corporation, Summit, NJ, USA, 2Market Access Solutions, Raritan, NJ, USA, 3Celgene Corporation, Berkeley Heights, NJ, USA
OBJECTIVES: In a Phase III clinical trial (Von Hoff, NEJM
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PCN40
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Oncology